vs
Foghorn Therapeutics Inc.（FHTX）与TRANSACT TECHNOLOGIES INC（TACT）财务数据对比。点击上方公司名可切换其他公司
TRANSACT TECHNOLOGIES INC的季度营收约是Foghorn Therapeutics Inc.的1.2倍（$11.5M vs $9.2M），Foghorn Therapeutics Inc.同比增速更快（223.8% vs 11.9%），过去两年Foghorn Therapeutics Inc.的营收复合增速更高（35.3% vs 3.5%）
Foghorn Therapeutics是一家临床阶段生物技术企业，专注于开发靶向染色质调控系统的创新疗法，用于治疗多种癌症及其他严重疾病，目前推进多款靶向候选药物管线，通过自主研发与战略合作服务全球患者群体。
该公司相关归属主体罗珀技术公司是一家控股集团，主要投资控股科技领域的各类企业，业务覆盖多个科技细分赛道，依托旗下子公司开展多元化科技业务布局。
FHTX vs TACT — 直观对比
营收规模更大
TACT
是对方的1.2倍
$9.2M
营收增速更快
FHTX
高出211.8%
11.9%
两年增速更快
FHTX
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.2M | $11.5M |
| 净利润 | $-21.7M | — |
| 毛利率 | — | 47.6% |
| 营业利润率 | -258.2% | -10.1% |
| 净利率 | -234.3% | — |
| 营收同比 | 223.8% | 11.9% |
| 净利润同比 | -11.1% | — |
| 每股收益（稀释后） | $-0.35 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FHTXTACT
| Q4 25 | $9.2M | $11.5M | ||
| Q3 25 | $8.2M | $13.2M | ||
| Q2 25 | $7.6M | $13.8M | ||
| Q1 25 | $6.0M | $13.1M | ||
| Q4 24 | $2.9M | $10.2M | ||
| Q3 24 | $7.8M | $10.9M | ||
| Q2 24 | $6.9M | $11.6M | ||
| Q1 24 | $5.0M | $10.7M |
净利润FHTXTACT
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-15.8M | $15.0K | ||
| Q2 25 | $-17.9M | $-143.0K | ||
| Q1 25 | $-18.8M | $19.0K | ||
| Q4 24 | $-19.5M | — | ||
| Q3 24 | $-19.1M | $-551.0K | ||
| Q2 24 | $-23.0M | $-319.0K | ||
| Q1 24 | $-25.0M | $-1.0M |
毛利率FHTXTACT
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
营业利润率FHTXTACT
| Q4 25 | -258.2% | -10.1% | ||
| Q3 25 | -226.9% | 0.1% | ||
| Q2 25 | -279.2% | -1.9% | ||
| Q1 25 | -385.0% | -0.1% | ||
| Q4 24 | -840.5% | -10.3% | ||
| Q3 24 | -305.5% | -7.7% | ||
| Q2 24 | -386.6% | -3.8% | ||
| Q1 24 | -558.3% | -12.2% |
净利率FHTXTACT
| Q4 25 | -234.3% | — | ||
| Q3 25 | -194.4% | 0.1% | ||
| Q2 25 | -237.3% | -1.0% | ||
| Q1 25 | -316.4% | 0.1% | ||
| Q4 24 | -682.9% | — | ||
| Q3 24 | -244.9% | -5.1% | ||
| Q2 24 | -333.6% | -2.8% | ||
| Q1 24 | -495.4% | -9.7% |
每股收益（稀释后）FHTXTACT
| Q4 25 | $-0.35 | $-0.11 | ||
| Q3 25 | $-0.25 | $0.00 | ||
| Q2 25 | $-0.28 | $-0.01 | ||
| Q1 25 | $-0.30 | $0.00 | ||
| Q4 24 | $-0.23 | $-0.80 | ||
| Q3 24 | $-0.31 | $-0.06 | ||
| Q2 24 | $-0.45 | $-0.03 | ||
| Q1 24 | $-0.59 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.9M | $20.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-108.5M | $31.1M |
| 总资产 | $198.1M | $44.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FHTXTACT
| Q4 25 | $80.9M | $20.4M | ||
| Q3 25 | $89.3M | $20.0M | ||
| Q2 25 | $72.6M | $17.7M | ||
| Q1 25 | $61.0M | $14.2M | ||
| Q4 24 | $55.5M | $14.4M | ||
| Q3 24 | $57.7M | $11.3M | ||
| Q2 24 | $138.9M | $11.1M | ||
| Q1 24 | $79.3M | $10.6M |
股东权益FHTXTACT
| Q4 25 | $-108.5M | $31.1M | ||
| Q3 25 | $-89.7M | $31.8M | ||
| Q2 25 | $-76.7M | $31.3M | ||
| Q1 25 | $-61.7M | $30.9M | ||
| Q4 24 | $-45.5M | $30.6M | ||
| Q3 24 | $-28.3M | $38.4M | ||
| Q2 24 | $-14.3M | $38.5M | ||
| Q1 24 | $-97.5M | $38.6M |
总资产FHTXTACT
| Q4 25 | $198.1M | $44.8M | ||
| Q3 25 | $205.0M | $45.0M | ||
| Q2 25 | $226.2M | $44.5M | ||
| Q1 25 | $258.7M | $44.2M | ||
| Q4 24 | $284.0M | $44.0M | ||
| Q3 24 | $308.4M | $50.5M | ||
| Q2 24 | $328.6M | $50.4M | ||
| Q1 24 | $255.0M | $51.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.3M | $609.0K |
| 自由现金流经营现金流 - 资本支出 | — | $589.0K |
| 自由现金流率自由现金流/营收 | — | 5.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $7.6M |
8季度趋势，按日历期对齐
经营现金流FHTXTACT
| Q4 25 | $-22.3M | $609.0K | ||
| Q3 25 | $-18.9M | $3.6M | ||
| Q2 25 | $-21.0M | $3.6M | ||
| Q1 25 | $-24.0M | $-161.0K | ||
| Q4 24 | $-24.5M | $2.4M | ||
| Q3 24 | $-21.0M | $327.0K | ||
| Q2 24 | $-25.5M | $636.0K | ||
| Q1 24 | $-29.3M | $-1.5M |
自由现金流FHTXTACT
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-21.0M | $3.6M | ||
| Q1 25 | $-24.0M | $-171.0K | ||
| Q4 24 | $-25.0M | $2.4M | ||
| Q3 24 | $-21.3M | $259.0K | ||
| Q2 24 | $-25.6M | $499.0K | ||
| Q1 24 | $-29.4M | $-1.6M |
自由现金流率FHTXTACT
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | -278.2% | 25.9% | ||
| Q1 25 | -403.2% | -1.3% | ||
| Q4 24 | -875.3% | 23.2% | ||
| Q3 24 | -273.0% | 2.4% | ||
| Q2 24 | -371.0% | 4.3% | ||
| Q1 24 | -583.1% | -14.9% |
资本支出强度FHTXTACT
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.3% | 0.1% | ||
| Q1 25 | 0.5% | 0.1% | ||
| Q4 24 | 16.8% | 0.1% | ||
| Q3 24 | 4.0% | 0.6% | ||
| Q2 24 | 0.2% | 1.2% | ||
| Q1 24 | 2.0% | 1.0% |
现金转化率FHTXTACT
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
